Vertex Pharmaceuticals’ Orkambi (lumacaftor+ivacaftor) Receives EU Approval for Cystic Fibrosis (CF) with Mutation in CFTR gene in Children Aged 2 to 5

 Vertex Pharmaceuticals’ Orkambi (lumacaftor+ivacaftor) Receives EU Approval for Cystic Fibrosis (CF) with Mutation in CFTR gene in Children Aged 2 to 5

Vertex Pharmaceuticals’ Orkambi (lumacaftor+ivacaftor) Receives EU Approval for Cystic Fibrosis (CF) with Mutation in CFTR gene in Children Aged 2 to 5

Shots:

  • The approval is based on two P-III clinical study result assessing Orkambi in 60 patients with CF + 2 copies of F508del mutation, in Children Aged 2 to 5
  • The studies demonstrated an improvement in sweat chloride, 2 EP @24 weeks (mean decrease in sweat chloride from baseline of 31.7 mmol/L; 95% CI: -35.7, -27.6, n=49)
  • Orkambi is a combination of lumacaftor and ivacaftor and being developed for Cystic Fibrosis. lumacaftor increase the amount of mature protein at the cell surface by targeting the processing and deals with defect of F508del-CFTR protein. Ivacaftor enhance the function of CFTR protein once it reaches the cell surface. It has already received EU approval for the treatment of CF in patients aged ≥ 6yr

Click here to read full press release/ article | Ref: Vertex Pharmaceuticals | Image: PJ Dionne Company, Inc

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post